Vama Lifecare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vama Lifecare Private Limited Pharmaceutical Export Portfolio Dataset — 14 Products, $1.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vama Lifecare Private Limited — Pharmaceutical Exporter Profile (2026) | 14 Products, $1.4M Trade | TransData Nexus

Vama Lifecare Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $1.4M Total Trade · DGFT Verified

Vama Lifecare Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.4M across 14 products in 3 therapeutic categories. Based on 376 verified export shipments from Indian Customs (DGFT) records, Vama Lifecare Private Limited is the #1 Indian exporter in 2 products including Daratumumab, Cetuximab. Top exports include Daratumumab ($268.2K), Cyclophosphamide ($204.4K), Ibrutinib ($203.2K).

Vama Lifecare Private Limited — Export Portfolio & Destination Treemap

Vama Lifecare Private Limited pharmaceutical export portfolio — 14 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vama Lifecare Private Limited? — Company Overview & Market Position

Vama Lifecare Private Limited, established on December 13, 2018, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24110MH2018PTC318267. Its authorized share capital is ₹500,000, with a paid-up capital of ₹100,000. The registered office is located at Unit No. 14, Peninsula Centre, Dr. S. S. Rao Road, Parel (E), Mumbai, Maharashtra, 400012.

Vama Lifecare specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans 14 products across three therapeutic categories: Advanced Oncology, Oncology, and Biologics & Immunotherapy. In the fiscal year 2023, Vama Lifecare reported a significant growth of 215.14% in total revenue, with a 534.11% increase in profit, and a 450.31% rise in net worth.

What Does Vama Lifecare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Daratumumab$268.2K 2

Product Portfolio — Top 14 by Export Value

Vama Lifecare Private Limited exports 14 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Daratumumab	Advanced Oncology	$268.2K	29	20.1%	1
2	Cyclophosphamide	Oncology	$204.4K	21	1.1%	8
3	Ibrutinib	Advanced Oncology	$203.2K	60	20.2%	2
4	Pembrolizumab	Advanced Oncology	$181.3K	19	9.4%	4
5	Ustekinumab	Biologics & Immunotherapy	$126.1K	55	9.9%	4
6	Cetuximab	Advanced Oncology	$95.8K	4	11.4%	1
7	Nivolumab	Advanced Oncology	$72.9K	7	3.2%	3
8	Mitomycin	Advanced Oncology	$70.1K	22	0.9%	8
9	Actinomycin	Advanced Oncology	$44.7K	59	1.5%	6
10	Osimertinib	Advanced Oncology	$43.1K	9	4.0%	6
11	Vinblastine	Oncology	$34.5K	20	4.6%	7
12	Pomalidomide	Advanced Oncology	$18.6K	32	0.4%	8
13	Thalidomide	Advanced Oncology	$17.6K	28	0.9%	10
14	Procarbazine	Advanced Oncology	$5.3K	11	2.0%	8

Vama Lifecare Private Limited exports 14 pharmaceutical products across 3 therapeutic categories with a total export value of $1.4M. The company is the #1 Indian exporter in 2 products: Daratumumab, Cetuximab. The top category is Advanced Oncology (73.7% of portfolio), followed by Oncology (17.2%), indicating a concentrated portfolio with the top 5 products accounting for 70.9% of total export value.

Vama Lifecare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vama Lifecare operates multiple manufacturing facilities across India, strategically located to serve both domestic and international markets. These facilities are equipped with state-of-the-art technology and adhere to stringent quality control measures to ensure the production of high-quality pharmaceutical formulations. The company specializes in the production of oncology drugs, critical care injectables, and biologics & immunotherapy products, catering to a diverse therapeutic portfolio.

3Key Leadership

The leadership team at Vama Lifecare is headed by Mr. Girish Ramesh Rathod, who serves as the Director. He co-founded the company in 2018 and has been instrumental in its growth and strategic direction. Another key figure is Ms. Shama Rathod Girish, also serving as a Director, contributing significantly to the company's operations and expansion initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vama Lifecare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vama Lifecare has made significant strides in penetrating regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully filed for regulatory approvals in these regions, ensuring compliance with their respective standards. This strategic approach has facilitated market access and established Vama Lifecare as a reliable supplier of pharmaceutical formulations in these territories.

2Emerging Markets

In addition to established markets, Vama Lifecare has expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality and regulatory compliance has enabled it to secure WHO prequalification, facilitating access to these regions. This expansion aligns with Vama Lifecare's mission to provide affordable and effective pharmaceutical solutions globally.

3Geographic Strategy

Vama Lifecare's geographic strategy demonstrates a balanced approach, with a strong presence in both regulated and emerging markets. This diversification mitigates concentration risk and positions the company for sustainable growth. The strategic direction focuses on expanding market reach while maintaining high standards of quality and compliance.

Vama Lifecare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Vama Lifecare has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring adherence to Good Manufacturing Practices (GMP). The company has filed Abbreviated New Drug Applications (ANDAs) for several products, facilitating market entry in the U.S. Additionally, Vama Lifecare has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about its manufacturing processes and quality control measures. The company's facilities have undergone FDA inspections, receiving favorable outcomes, which underscores its commitment to maintaining high-quality standards.

2WHO & EU GMP

Vama Lifecare has achieved WHO prequalification for several of its products, affirming their compliance with international quality standards. The company holds EU GMP certificates, demonstrating its adherence to European manufacturing standards. These certifications enhance Vama Lifecare's credibility and facilitate access to global markets.

3CDSCO & Indian Regulatory

Vama Lifecare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vama Lifecare operates in a competitive landscape, with several key players in the pharmaceutical export sector. The company's focus on high-quality oncology drugs, critical care injectables, and biologics & immunotherapy products positions it favorably in the market. While specific market share data is not publicly disclosed, Vama Lifecare's strategic focus on quality and regulatory compliance differentiates it from competitors.

2Key Differentiators

Vama Lifecare's key differentiators include its extensive experience in specialty medicine, a diverse product portfolio, and a strong commitment to quality and regulatory compliance. The company's focus on patient safety and its ability to deliver reliable, affordable, and effective pharmaceutical solutions worldwide further distinguish it in the market.

3Strategic Position

Vama Lifecare's current strategic direction emphasizes the development and export of generic pharmaceutical formulations, with a particular focus on oncology, critical care, and biologics & immunotherapy products. The company's future outlook includes expanding its presence in both regulated and emerging markets, leveraging its manufacturing capabilities and regulatory approvals to drive growth.

Buyer Due Diligence Brief — Evaluating Vama Lifecare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vama Lifecare has demonstrated a strong track record in pharmaceutical manufacturing, with a consistent export volume and a diverse product portfolio. The company's adherence to international quality standards and regulatory compliance indicators, such as WHO prequalification and EU GMP certifications, underscore its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Vama Lifecare as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO Prequalification: Ensure that the company's products are prequalified by the World Health Organization.

EU GMP Certification: Verify the company's compliance with European Good Manufacturing Practices.

Frequently Asked Questions — Vama Lifecare Private Limited

How many pharmaceutical products does Vama Lifecare Private Limited export from India?

Vama Lifecare Private Limited exports 14 pharmaceutical products across 3 therapeutic categories. The top exports are Daratumumab ($268.2K), Cyclophosphamide ($204.4K), Ibrutinib ($203.2K), Pembrolizumab ($181.3K), Ustekinumab ($126.1K). Total export value is $1.4M.

What is Vama Lifecare Private Limited's total pharmaceutical export value?

Vama Lifecare Private Limited's total pharmaceutical export value is $1.4M, based on 376 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Vama Lifecare Private Limited the #1 Indian exporter?

Vama Lifecare Private Limited is the #1 Indian exporter in 2 products: Daratumumab (20.1% market share), Cetuximab (11.4% market share).

What therapeutic categories does Vama Lifecare Private Limited cover?

Vama Lifecare Private Limited exports across 3 therapeutic categories. The largest are Advanced Oncology (73.7%, 11 products), Oncology (17.2%, 2 products), Biologics & Immunotherapy (9.1%, 1 products).

Get Full Vama Lifecare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.